drugset / Trial / NCT04716881
Pharmacokinetic Study of Vivitrol in Healthy Participants
Phase 1
Completed
9 enrolled
Go Medical Industries Pty Ltd
Clinilabs, Inc. · collabColumbia University · collabNational Institute on Drug Abuse (NIDA) · collabNew York State Psychiatric Institute · collab
NaSingle-groupOpen-labelBasic science
Summary
This is a Phase I, single-center, single arm, open-label study, to establish the pharmacokinetic (PK) parameters of Vivitrol 380 mg IM injection (IP), a US Food and Drug Administration (FDA) approved medication.
Timeline
- Start
- 2021-01-25
- Primary completion
- 2022-04-04
- Completion
- 2022-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | 380 mg | Intramuscular |